Yao‐Tseng Chen

Active 1997–2022

Also published as
Yao-Tseng Chen · Yao‐Tseng Chen. · Yao Tseng Chen
71
Papers
19,461
Citations
66
h-index
71
i10-index

Citations

Citations per year for Yao‐Tseng Chen1993: 1 citations1996: 1 citations1997: 3 citations1998: 37 citations1999: 70 citations2000: 158 citations2001: 201 citations2002: 244 citations2003: 193 citations2004: 209 citations2005: 231 citations2006: 219 citations2007: 190 citations2008: 209 citations2009: 201 citations2010: 208 citations2011: 229 citations2012: 166 citations2013: 147 citations2014: 145 citations2015: 179 citations2016: 159 citations2017: 155 citations2018: 164 citations2019: 463 citations2020: 425 citations2021: 398 citations2022: 262 citations2023: 189 citations2024: 229 citations2025: 88 citations2026: 2 citations1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,797 citing papers, 32.8% of this breakdownChina: 568 citing papers, 10.4% of this breakdownGermany: 358 citing papers, 6.6% of this breakdownUnited Kingdom: 286 citing papers, 5.2% of this breakdownJapan: 241 citing papers, 4.4% of this breakdownFrance: 202 citing papers, 3.7% of this breakdownItaly: 200 citing papers, 3.7% of this breakdownCanada: 176 citing papers, 3.2% of this breakdownAustralia: 166 citing papers, 3% of this breakdownSwitzerland: 165 citing papers, 3% of this breakdownNetherlands: 127 citing papers, 2.3% of this breakdownSpain: 105 citing papers, 1.9% of this breakdown
0%32.8%Other 19.8%

Fields

  • Medicine40.1%
  • Immunology and Microbiology32.8%
  • Biochemistry, Genetics and Molecular Biology24.6%
  • Agricultural and Biological Sciences0.5%
  • Engineering0.5%
  • Neuroscience0.5%
  • Other1%

Topics

  • Immunotherapy and Immune Responses14.7%
  • Cancer Immunotherapy and Biomarkers8.9%
  • Immune Cell Function and Interaction6.4%
  • CAR-T cell therapy research4.6%
  • T-cell and B-cell Immunology3.7%
  • vaccines and immunoinformatics approaches3.3%
  • Other58.4%

Coauthors

All papers

Open in search
  1. Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 + /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 2,389

  2. Cancer/testis antigens, gametogenesis and cancer

    Authors: , , , , - Nature reviews. Cancer 2005 cited by 1,596

  3. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1997 cited by 1,245

  4. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

    Authors: , , , , , , , , , , , , , , , , , , - Nucleic Acids Research, Nucleic Acids Res. 2008 cited by 440

  5. Genome-wide analysis of cancer/testis gene expression

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 338

  6. Cancer/testis (CT) antigens: Potential targets for immunotherapy

    Authors: , - Cancer Science 2009 cited by 556

  7. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

    Authors: , , , , , , , , , , , - The Journal of Experimental Medicine 1998 cited by 725

  8. NY‐ESO‐1: Review of an Immunogenic Tumor Antigen

    Authors: , , , , , , , , - Advances in cancer research 2006 cited by 455

  9. Bcl-xL promotes metastasis independent of its anti-apoptotic activity

    Authors: , , , , , , , , , - Nature Communications 2016 cited by 106

  10. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

    Authors: , , , , - Immunological Reviews 2002 cited by 880

  11. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

    Authors: , , , , , , , , , - International Journal of Cancer 2001 cited by 348

  12. Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells

    Authors: , , , , , , , , , , , , , , , - Cancer Letters 2022 cited by 34

  13. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.

    Authors: , , , , , , , , , , , , , , , , , - 2003 cited by 252

  14. Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

    Authors: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 201

  15. Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL

    Authors: , , , , , , , , , , , - The Journal of Immunology 2000 cited by 175

  16. Expression of cancer/testis (CT) antigens in lung cancer

    Authors: , , , , , , , , , , - Lung Cancer 2003 cited by 137

  17. Tissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2

    Authors: , , , , - American Journal of Clinical Pathology 2012 cited by 110

  18. A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

    Authors: , , , , , , , , - The Journal of Experimental Medicine 1998 cited by 696

  19. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2000 cited by 398

  20. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer

    Authors: , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2000 cited by 237

  21. Expression of MAGE-antigens in normal tissues and cancer

    Authors: , , , , , , , - International Journal of Cancer 2000 cited by 217

  22. Expression of the Receptor for Hyaluronic Acid–Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression

    Authors: , , , , , - Applied immunohistochemistry & molecular morphology 2019 cited by 21

  23. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2004 cited by 440

  24. Colon cancer associated transcript‐1: A novel RNA expressed in malignant and pre‐malignant human tissues

    Authors: , , , , , , , , , , , , , , - International Journal of Cancer 2011 cited by 289